Distribution · GCC · Announced 25 Sept 2026
Cordex Biologics → Farma Mondo
Zemcelpro reaches the GCC through a Swiss specialty-access intermediary focused on early access, rather than through a local pharma partner.
Parties: Cordex Biologics (Canada) → Farma Mondo SA (Switzerland)
- Deal type
- Distribution
- Value
- Not stated
- Territory
- Saudi Arabia + United Arab Emirates (added to an existing Farma Mondo deal that already covered Argentina, Hong Kong, Singapore)
- Therapeutic area
- Oncology
- Asset
- Zemcelpro® (dorocubicel / UM171 Cell Therapy) — personalized cryopreserved allogeneic HSCT product
- Announced
- 25 Sept 2026
Our analysis
This is an expansion of an existing Cordex–Farma Mondo distribution agreement (announced 16 Jul 2026 for Argentina, Hong Kong, Singapore) to now include Saudi Arabia and the UAE. Farma Mondo doesn't license or manufacture — it provides regulatory, market-access and specialty-distribution services, with an explicit early-access focus (getting the therapy to eligible patients ahead of full reimbursement). So the GCC gets access to Zemcelpro through a Swiss specialty-access intermediary , not a local pharma partner — a distinct model from the licence-and-localize deals elsewhere in your tracker.
The full analysis is free to read with a work email on this page.
Source: Bio Spectrum Asia